Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp. (MDNA.TO) Financial Performance & Income Statement Overview
Analyze Medicenna Therapeutics Corp. (MDNA.TO) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Medicenna Therapeutics Corp. (MDNA.TO) Income Statement & Financial Overview
View the income breakdown for Medicenna Therapeutics Corp. MDNA.TO across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $5000.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $5000.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $1.00 |
| R&D Expenses | $4.49M | $3.44M | $3.73M | $2.78M |
| SG&A Expenses | $1.21M | $1.66M | $1.79M | $1.25M |
| Operating Expenses | $5.72M | $5.12M | $5.53M | $4.04M |
| Total Costs & Expenses | $5.72M | $5.12M | $5.53M | $4.04M |
| Interest Income | $264000.00 | $378000.00 | $378000.00 | $330000.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $19000.00 | $18000.00 | $11000.00 | $5000.00 |
| EBITDA | -$5.70M | -$5.10M | -$5.52M | -$4.04M |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | -$807.00 |
| Operating Income | -$5.72M | -$5.12M | $0.00 | -$4.04M |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | -$808.00 |
| Other Income/Expenses (Net) | $6.91M | -$71000.00 | $1.36M | $403000.00 |
| Income Before Tax | $157000.00 | -$5.19M | -$4.16M | -$3.64M |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | -$727.40 |
| Income Tax Expense | -$1.03M | $0.00 | -$195000.00 | $0.00 |
| Net Income | $1.19M | -$5.19M | -$4.16M | -$3.64M |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | -$727.40 |
| EPS | $0.02 | -$0.07 | -$0.05 | -$0.05 |
| Diluted EPS | $0.02 | -$0.07 | -$0.05 | -$0.05 |
| Weighted Avg Shares Outstanding | $78.22M | $78.009M | $76.84M | $73.62M |
| Weighted Avg Shares Outstanding (Diluted) | $78.22M | $78.009M | $76.84M | $73.62M |
Financial performance has remained strong, with revenue growing from $5000.00 in Q1 2024 to $0.00 in Q4 2024. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$5.72M in Q4 2024, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$5.70M. Net income rose to $1.19M, keeping EPS at $0.02. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan